Tags

Type your tag names separated by a space and hit enter

Yellow fever vaccines and international travelers.
Expert Rev Vaccines. 2008 Jul; 7(5):579-87.ER

Abstract

The growth of air travel has diminished the barriers to the spread of yellow fever, posing a threat to regions that have not previously been reached by the disease but are considered receptive, including the Middle East, coastal East Africa, the Indian subcontinent, Asia and Australia. For many decades, vaccination against yellow fever has been required for travelers entering many countries with receptive mosquito vectors in order to prevent the importation of yellow fever virus from a country that had ongoing transmission. Each year, approximately 9 million tourists travel to countries where yellow fever is endemic; the number of tourists who visit yellow fever-endemic regions within these countries may exceed 3 million. Risk estimates of yellow fever to travelers are extremely difficult to ascertain due to fluctuation of the disease by year and season, incomplete surveillance data, and lack of accurate data regarding vaccine coverage of the local population. The 17D live yellow fever vaccine has been widely acknowledged as one of the most effective and safe vaccines in use. Recently, however, reports of severe and previously unrecognized significant adverse events linked to the 17D vaccine have caused major concern. Some have called for the development of new inactivated yellow fever vaccines for travelers. A new approach for manufacturing the live 17D vaccine involves using a full-length cDNA clone of 17D-204 virus. This new method allows production in a cell culture system and potentially reduces the risk of adventitious viruses and selection of a subpopulation during replication, thereby increasing safety.

Authors+Show Affiliations

Maxwell Finalnd Laborator for Infectious Diseases, Boston Medical Center, Boston, MA, USA. elizabeth.barnett@bmc.orgNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

18564013

Citation

Barnett, Elizabeth D., et al. "Yellow Fever Vaccines and International Travelers." Expert Review of Vaccines, vol. 7, no. 5, 2008, pp. 579-87.
Barnett ED, Wilder-Smith A, Wilson ME. Yellow fever vaccines and international travelers. Expert Rev Vaccines. 2008;7(5):579-87.
Barnett, E. D., Wilder-Smith, A., & Wilson, M. E. (2008). Yellow fever vaccines and international travelers. Expert Review of Vaccines, 7(5), 579-87. https://doi.org/10.1586/14760584.7.5.579
Barnett ED, Wilder-Smith A, Wilson ME. Yellow Fever Vaccines and International Travelers. Expert Rev Vaccines. 2008;7(5):579-87. PubMed PMID: 18564013.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Yellow fever vaccines and international travelers. AU - Barnett,Elizabeth D, AU - Wilder-Smith,Annelies, AU - Wilson,Mary E, PY - 2008/6/20/pubmed PY - 2008/8/16/medline PY - 2008/6/20/entrez SP - 579 EP - 87 JF - Expert review of vaccines JO - Expert Rev Vaccines VL - 7 IS - 5 N2 - The growth of air travel has diminished the barriers to the spread of yellow fever, posing a threat to regions that have not previously been reached by the disease but are considered receptive, including the Middle East, coastal East Africa, the Indian subcontinent, Asia and Australia. For many decades, vaccination against yellow fever has been required for travelers entering many countries with receptive mosquito vectors in order to prevent the importation of yellow fever virus from a country that had ongoing transmission. Each year, approximately 9 million tourists travel to countries where yellow fever is endemic; the number of tourists who visit yellow fever-endemic regions within these countries may exceed 3 million. Risk estimates of yellow fever to travelers are extremely difficult to ascertain due to fluctuation of the disease by year and season, incomplete surveillance data, and lack of accurate data regarding vaccine coverage of the local population. The 17D live yellow fever vaccine has been widely acknowledged as one of the most effective and safe vaccines in use. Recently, however, reports of severe and previously unrecognized significant adverse events linked to the 17D vaccine have caused major concern. Some have called for the development of new inactivated yellow fever vaccines for travelers. A new approach for manufacturing the live 17D vaccine involves using a full-length cDNA clone of 17D-204 virus. This new method allows production in a cell culture system and potentially reduces the risk of adventitious viruses and selection of a subpopulation during replication, thereby increasing safety. SN - 1744-8395 UR - https://www.unboundmedicine.com/medline/citation/18564013/Yellow_fever_vaccines_and_international_travelers_ L2 - https://www.tandfonline.com/doi/full/10.1586/14760584.7.5.579 DB - PRIME DP - Unbound Medicine ER -